Akari Therapeutics Plc - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Akari Therapeutics Plc on October 15, 2025. The filing serves to disclose a material event under Item 7.01 (Regulation FD Disclosure) regarding a capital raise.
Key Financial Metrics
The filing announces a Registered Direct Offering with a total value of $2.5 million. The document does not provide specific figures for revenue, profit, cash flow, operating margins, existing debt levels, or overall liquidity positions as of the reporting date.
Material Changes
The primary material change reported is the execution of a $2.5 million Registered Direct Offering. No comparative financial data or changes versus prior periods are included in this specific filing text.
Guidance, Outlook, and Risks
The filing references a press release (Exhibit 99.1) titled "Akari Therapeutics Announces $2.5 Million Registered Direct Offering" but does not contain the full text of management commentary, future guidance, or specific risk factors within the body of this 8-K. The filing explicitly states that the information is "furnished" and not "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the full terms of the $2.5 million Registered Direct Offering in the attached press release (Exhibit 99.1).
- Confirm the number of shares issued and the price per share in the offering.
- Review the company's most recent 10-Q or 10-K for current cash balance and burn rate to assess the impact of this capital raise on liquidity.
- Check for any underwriting agreements or lock-up provisions associated with the offering.